[{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jnana Therapeutics To Advance JNT-517 As Development Candidate And Potential First-In-Class Oral Treatment For PKU","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"JNT-517","moa":"SLC6A19","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Jnana Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jnana Ther.."},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jnana Therapeutics to Present Preclinical Data for its PKU Program at the 2022 National PKU Alliance (NPKUA) Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"JNT-517","moa":"SLC6A19","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Jnana Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jnana Ther.."},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$107.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platform","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series C Financing","leadProduct":"JNT-517","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Jnana Therapeutics","amount2":0.11,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Jnana Ther.."},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jnana Therapeutics Announces FDA Clearance of IND Application for JNT-517 for the Treatment of Phenylketonuria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"JNT-517","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Jnana Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jnana Ther.."},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,125.0 million","upfrontCash":"$800.0 million","newsHeadline":"Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"JNT-517","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Jnana Therapeutics","amount2":1.1299999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":null,"companyTruncated":"Jnana Ther.."}]